(Q42639115)

English

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

scientific article published on November 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

12

object named as

Tom Mikkelsen

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Kathryn A Carson

10

object named as

Kathryn Carson

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

E Antonio Chiocca

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Khalid M Abbed

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Stephen Tatter

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

David N Louis

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Fred H Hochberg

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Fred Barker

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Jean Kracher

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Stuart A Grossman

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Joy D Fisher

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Mark Rosenblum

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Jeff Olson

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

James Markert

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Steven Rosenfeld

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Steven Brem

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Surasak Phuphanich

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Scott Freeman

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Rick Kaplan

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

James Zwiebel

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 November 2004

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Molecular Therapy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

958-966

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15509513%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

The WHO classification of tumors of the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Current and future strategies for the treatment of malignant brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Oncolytic viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Adenovirus gene transfer causes inflammation in the brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Adenovirus infection induces microglial activation: involvement of mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.07.021

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42639115&oldid=2127633872"